Biotech · Private company
ViiV Healthcare
Track this companyFree. Adds ViiV Healthcare to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs48From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline48
- 2 NRTIs plus an INI, NNRTI, or PIPhase 3 · Infection, Human Immunodeficiency VirusClinicalTrials.gov · fetched Nov 12, 2026
- ABC/DTG/3TC STR - TabletPhase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- BMS-663068Phase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- CAB LAPhase 3 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- CAB LA + RPV LAPhase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- CAB ULAPhase 3 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- Cabotegravir - Injectable Suspension (CAB LA)Phase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Cabotegravir - Injectable Suspension (CAB LA)Phase 3 · Infection, Human Immunodeficiency VirusClinicalTrials.gov · fetched Nov 12, 2026
- Cabotegravir (CAB) tabletPhase 3 · Infection, Human Immunodeficiency VirusClinicalTrials.gov · fetched Nov 12, 2026
- Cabotegravir (CAB) tabletPhase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Cabotegravir Injectable SuspensionPhase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Cabotegravir TabletsPhase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- DTG TabletPhase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Oral ARTPhase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Rilpivirine - Injectable Suspension (RPV LA)Phase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Rilpivirine - Injectable Suspension (RPV LA)Phase 3 · Infection, Human Immunodeficiency VirusClinicalTrials.gov · fetched Nov 12, 2026
- Rilpivirine (RPV) tabletPhase 3 · Infection, Human Immunodeficiency VirusClinicalTrials.gov · fetched Nov 12, 2026
- Rilpivirine (RPV) tabletPhase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Rilpivirine Injectable SuspensionPhase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Rilpivirine TabletsPhase 3 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- RPV LAPhase 3 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- RPV ULAPhase 3 · HIVClinicalTrials.gov · fetched Nov 12, 2026
- CAB LAPhase 2 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- CabotegravirPhase 2 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Dolutegravir / Lamivudine (DTG/3TC)Phase 2 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tabletsPhase 2 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- New formulation of CAB LAPhase 2 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- rHuPH20Phase 2 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- VH3810109Phase 2 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- VH4524184Phase 2 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- CAB >=400 mg/mLPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- CAB Formulation IPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- CAB Formulation JPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- CAB ULAPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Cabotegravir 200 mg/mLPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Cabotegravir long-actingPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Fostemsavir (FTR)Phase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Lenacapavir long-actingPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Oral VH4524184Phase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- RPVPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- SOC INSTI-based ARTPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- VH4011499 high dose InjectionPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- VH4011499 low dose InjectionPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- VH4367310Phase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- VH4524184 Formulation A SCPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- VH4524184 Formulation B SCPhase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- VH4770359Phase 1 · HIV InfectionsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Reaching Persons With HIV Who Are Out of Care Through Expedited Access to Long-Acting Injectable Antiretroviral Therapy - The RELAI StudyPHASE4 · NOT_YET_RECRUITING · started Jan 1, 2027ClinicalTrials.gov NCT07895823 · fetched Nov 12, 2026
- A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult ParticipantsPHASE1 · RECRUITING · started Sep 15, 2026ClinicalTrials.gov NCT07818915 · fetched Nov 12, 2026
- A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedPHASE3 · RECRUITING · started Jun 25, 2026ClinicalTrials.gov NCT07650916 · fetched Nov 12, 2026
- A Study to Investigate the Safety and PK of VH4770359 in Healthy ParticipantsPHASE1 · RECRUITING · started May 14, 2026ClinicalTrials.gov NCT07525544 · fetched Nov 12, 2026
- Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject DrugsPHASE4 · RECRUITING · started Feb 24, 2026ClinicalTrials.gov NCT07199335 · fetched Nov 12, 2026
- A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)PHASE2 · RECRUITING · started Feb 11, 2026ClinicalTrials.gov NCT07202546 · fetched Nov 12, 2026
- A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 10, 2025ClinicalTrials.gov NCT07053384 · fetched Nov 12, 2026
- A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIVPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 22, 2025ClinicalTrials.gov NCT06970223 · fetched Nov 12, 2026
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy AdultsPHASE1 · ACTIVE_NOT_RECRUITING · started Jan 17, 2025ClinicalTrials.gov NCT06786520 · fetched Nov 12, 2026
- A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 20, 2024ClinicalTrials.gov NCT06741397 · fetched Nov 12, 2026
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIVPHASE1 · RECRUITING · started Dec 16, 2024ClinicalTrials.gov NCT06724640 · fetched Nov 12, 2026
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 2, 2024ClinicalTrials.gov NCT06694805 · fetched Nov 12, 2026
- Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social NeedsPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 1, 2024ClinicalTrials.gov NCT06411223 · fetched Nov 12, 2026
- IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan AreasACTIVE_NOT_RECRUITING · started Jul 1, 2024ClinicalTrials.gov NCT06451341 · fetched Nov 12, 2026
- First Time in Human Study of Long Acting VH4524184 FormulationsPHASE1 · RECRUITING · started Mar 21, 2024ClinicalTrials.gov NCT06310551 · fetched Nov 12, 2026
- Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in BotswanaPHASE4 · ACTIVE_NOT_RECRUITING · started Nov 30, 2023ClinicalTrials.gov NCT05986084 · fetched Nov 12, 2026
- A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)PHASE2 · ACTIVE_NOT_RECRUITING · started Aug 17, 2023ClinicalTrials.gov NCT05996471 · fetched Nov 12, 2026
- Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER StudyPHASE4 · ACTIVE_NOT_RECRUITING · started Jun 15, 2022ClinicalTrials.gov NCT05220358 · fetched Nov 12, 2026
- A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsPHASE1 · RECRUITING · started Jun 14, 2022ClinicalTrials.gov NCT05418868 · fetched Nov 12, 2026
- Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 27, 2017ClinicalTrials.gov NCT03299049 · fetched Nov 12, 2026
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 28, 2016ClinicalTrials.gov NCT02951052 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsPHASE3 · ACTIVE_NOT_RECRUITING · started Oct 27, 2016ClinicalTrials.gov NCT02938520 · fetched Nov 12, 2026
- Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV InfectionPHASE4 · ACTIVE_NOT_RECRUITING · started Dec 1, 2015ClinicalTrials.gov NCT02656511 · fetched Nov 12, 2026
- Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 23, 2015ClinicalTrials.gov NCT02362503 · fetched Nov 12, 2026
- Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.RECRUITING · started Jan 1, 1989ClinicalTrials.gov NCT00404989 · fetched Nov 12, 2026